Quimioterapia adyuvante: seguimiento
Palabras clave:
cáncer de recto, Cirugía colorrectalResumen
Artículo especial: capítulo 9 de la “Guía práctica para el tratamiento quirúrgico del cáncer de recto" del Grupo Gallego de Coloproctología y la Sociedad de Cirugía de Galicia.
Descargas
Citas
André T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27:3109-16. Doi: 10.1200/JCO.2008.20.6771.
Glynne Jóns R., Wyrwicz L., Tiret E., Brown G., Rödel C., Cervantes A., et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnose, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv22-iv40. Doi: 10.1093/annonc/mdx 224.
Petersen S. H., Harling H., Kirkeby L. T., Wille Jørgensen P., Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 2012(3):CD004078.
Sainato A., Cernusco Luna Nunzia V., Valentini V., De Paoli A., Maurizi E. R., Lupattelli M., et al. Non benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014; 113:223-9. Doi: 10.1016/j.radonc.2014. 10.006.
Glynne Jóns R., Counsell N., Quirke P., Mortensen N., Maraveyas A., Meadows H. M., et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014; 25:1356-1362. Doi: 10.1093/annonc/mdu147.
Breugom A. J., van Gijn W., Muller E. W., Berglund Å., van den Broek C. B. M., Fokstuen T., et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015; 26:696-701. Doi: 10.1093/annonc/mdu560.
Breugom A. J., Swets M., Bosset J. F., Collette L., Sainato A., Cionini L., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015; 16:200-7
Maas M., Nelemans P. J., Valentini V., Crane C. H., Capirci C., Rödel C., et al. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3, 313 patients. Int J Cancer. 2015 1; 137:212-20. Doi: 10.1002/ijc.29355.
Carvalho C., Glynne Jóns R. Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol. 2017; 18:e354-e363. Doi: 10.1016/S1470-2045(17)30346-7. Erratum in: Lancet Oncol. 2018; 19:e137.
Zhao L., Liu R., Zhang Z., Li T., Li F., Liu H., et al. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Colorectal Dis. 2016; 18:763-72. Doi: 10.1111/codi.13381.
Petrelli F., Coinu A., Lonati V., Barni S. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis. 2015; 30:447-57. Doi: 10.1007/s00384-014-2082-9.
Hong Y. S., Kim S. Y., Le J. S., Nam B. H., Kim K. P., Kim J. E., et al. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. J Clin Oncol. 2019; 37:3111-23. Doi: 10.1200/ JCO.19.00016.
Rödel C., Liersch T., Becker H., Fietkau R., Hohenberger W., Hothorn T., et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012; 13:679-87. Doi: 10.1016/S1470-2045(12)70187-0.
Dossa F., Acuna S. A., Rickles A. S., Berho M., Wexner S. D., Quereshy F. A., et al. Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. JAMA Oncol. 2018; 4:930-7. Doi: 10.1001/jamaoncol.2017.5597. PMID: 29710274; PMCID: PMC6145724.
Ma B., Ren E., Chen E., Lian B., Jiang P., Li E., et al. Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis. Int J Colorectal Dis. 2019; 34:113-21. Doi: 10.1007/s00384-018-3181-9.
Polanco P. M., Mokdad A. A., Zhu H., Choti M. A., Huerta S. Association of Adjuvant Chemotherapy With Overall Survival in Patients With Rectal Cancer and Pathologic Complete Response Following Neoadjuvant Chemotherapy and Resection. JAMA Oncol. 2018; 4:938-43. Doi: 10.1001/jamaoncol.2018.0231.
Hu X., Li Y. Q., Li Q. G., Ma Y. L., Peng J. J., Cai S. J. Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis. Oncologist. 2019; 24:803-11. Doi: 10.1634/theoncologist.2017-0600
Steele S. R., Chang G. J., Hendren S., Weiser M., Irani J., Buie W. D., et al. Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2015; 58:713-25. Doi: 10.1097/ DCR.0000000000000410.
Bastiaenen V. P., Hovdenak Jakobsen I., Labianca R., Martling A., Morton D. G., Primrose J. N., et al. Research Committee and the Guidelines Committee of the European Society of Coloproctology (ESCP). Consensus and controversies regarding follow-up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology. Colorectal Dis. 2019; 21:392-416. Doi: 10.1111/codi.14503.
Wille Jørgensen P., Syk I., Smedh K., Laurberg S., Nielsen D. T., Petersen S. H., et al. Effect of More vs. Less Frequent Follow-up Testing on Overall and Colorectal Cancer-Specific Mortality in Patients With Stage II or III Colorectal Cancer: The COLOFOL Randomized Clinical Trial. JAMA. 2018; 319:2095-103. Doi: 10.1001/jama.2018.5623.
Rosati G., Ambrosini G., Barni S., Andreoni B., Corradini G., Luchena G., et al. A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma. Ann Oncol. 2016; 27:274-80. Doi: 10.1093
Tjandra J. J., Chan M. K. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum. 2007; 50:1783-99. Doi: 10.1007/s10350-007-9030-5.
Mokhles S., Macbeth F., Farewell V., Fiorentino F., Williams N. R., Younes R. N., et al. Meta-analysis of colorectal cancer follow-up after potentially curative resection. Br J Surg. 2016; 103:1259-68. Doi: 10.1002/bjs.10233.
Jeffery M., Hickey B. E., Hider P. N. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2019 4; 9:CD002200. Doi: 10.1002/14651858. CD002200.
Secco G. B., Fardelli R., Gianquinto D., Bonfante P., Baldi E., Ravera G., et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol. 2002; 28:418-23. Doi: 10.1053/ejso.2001.1250.
Rodríguez Moranta F., Saló J., Arcusa A., Boadas J., Piñol V., Bessa X., et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol. 2006; 24:386-93. Doi: 10.1200/JCO. 2005.02.0826.
Renehan A. G., Egger M., Saunders M. P., O’Dwyer S. T. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002; 324(7341):813. Doi: 10.1136/bmj.324.7341.813.
Pita Fernández S., Alhayek Aí M., González Martín C., López Calviño B., Seoane Pillado T., Pértega Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Ann Oncol. 2015; 26:644-56. Doi: 10.1093/annonc/mdu543.
Zhao E., Yi C., Zhang E., Fang F., Faramand A. Intensive follow-up strategies after radical surgery for nonmetastatic colorectal cancer: A systematic review and meta-analysis of randomized controlled trials. PLoS One. 2019; 14:e0220533. Doi: 10.1371/journal.pon.0220533.
Hardiman K. M., Felder S. I., Friedman G., Migaly J., Paquette I. M., Feingold D. L. Prepared on behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surveillance and Survivorship Care of Patients After Curative Treatment of Colon and Rectal Cancer. Dis Colon Rectum. 2021; 64:517-33. Doi: 10.1097/DCR.0000000000001984.
Godhi S., Godhi A., Bhat R., Saluja S. Colorectal Cancer: Postoperative Follow-up and Surveillance. Indian J Surg. 2017; 79:234-7. Doi: 10.1007/s12262-017-1610-6.
Frontali A., Benichou B., Valcea I., Maggiori L., Prost À a Denise J., Panis E. Is follow-up still mandatory more than 5 years after surgery for colorectal cancer? Updates Surg. 2020; 72:55-60. Doi: 10.1007/s13304-019-00678-5.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 A. Carral Maseda, I. Bermúdez Pestorit, M.O. Maseda Díaz
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
